Among men with localized high-risk prostate cancer (PCa), patients who meet very high-risk (VHR) criteria have been shown to experience worse outcomes after radical prostatectomy (RP) in a previous study. Variations of VHR criteria have been suggested to be prognostic in other single-center cohorts, but multicenter outcomes validating VHR criteria have not been described. This study was designed to validate VHR criteria for identifying which PCa patients are at greatest risk for cancer progression. METHODS: Patients with high-risk PCa undergoing RP (2005RP ( -2015 at 3 tertiary centers were pooled. The outcomes of men with VHR PCa were compared with the outcomes of those who did not meet VHR criteria. The high-risk criteria were a clinical stage of T3 to T4, a prostate-specific antigen level > 20 ng/mL, or a biopsy Gleason grade sum of 8 to 10. The VHR criteria were multiple high-risk features, >4 biopsy cores with a Gleason grade sum of 8 to 10, or primary Gleason grade pattern 5. Biochemical recurrence, metastasis (METS), and cancer-specific mortality (CSM) were assessed with competing risks regressions. Overall mortality was assessed with Cox survival models. RESULTS: Among 1981 patients with high-risk PCa, men with VHR PCa (n = 602) had adverse pathologic outcomes: 37% versus 25% for positive margins and 37% versus 15% for positive lymph nodes (P < .001 for both comparisons). Patients with VHR PCa also had higher adjusted hazard ratios for METS (2.78; 95% confidence interval [CI], 2.08-3.72), CSM (6.77; 95% CI, 2.91-15.7), and overall mortality (2.44; 95% CI, 1.56-3.80; P < .001 for all comparisons). CONCLUSIONS: In a validation study of patients who underwent treatment for high-risk PCa, VHR criteria were strongly associated with adverse pathologic and oncologic outcomes. Cancer 2019;125:391-397.
INTRODUCTION
Oncologic outcomes after the definitive treatment of localized prostate cancer (PCa) can be predicted with reasonable accuracy on the basis of the clinical/pathologic stage, tumor grade, pretreatment prostate-specific antigen (PSA) level, and results of systematic biopsy, and several validated prediction models for predicting these outcomes exist. 1, 2 High-risk PCa is defined by the following criteria: biopsy Gleason sum of 8 to 10, serum PSA level > 20 ng/mL, or clinical stage ≥ T3. 3 However, even within the high-risk classification, there is a wide range of outcomes: rates of 10-year freedom from biochemical recurrence (BCR) and metastasis (METS) can vary widely (from 25% to 68% and from 73% to 89%, respectively). [4] [5] [6] [7] [8] [9] [10] Therefore, there is a growing consensus that not all high-risk PCa cases have equivalent lethal potential, and they perhaps should not be treated the same. Previously, we derived a new risk stratum, very high-risk (VHR) PCa, and we showed that VHR criteria (defined as primary Gleason pattern 5 on biopsy, >4 biopsy cores with a Gleason sum of 8-10, or multiple individual National Comprehensive Cancer Network [NCCN] high-risk features) appear to identify men with distinctly worse oncologic outcomes after radical prostatectomy (RP). 5 Subsequently, VHR criteria were shown to also identify men with markedly higher rates of METS and PCa-specific mortality in a cohort treated with definitive radiation therapy (RT) plus androgen deprivation therapy (ADT).
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Here we sought to determine whether VHR criteria retain prognostic significance in a validation study by pooling patients with high-risk PCa who underwent RP at 3 independent tertiary centers.
MATERIALS AND METHODS

Study Cohort
Consecutively presenting patients who underwent RP at The University of Texas MD Anderson Cancer Center, Johns Hopkins, and the Cleveland Clinic were identified with prospectively maintained PCa registries at each institution. Patients who underwent RP between 2005 and 2015 were included in the study to reflect contemporary pathologic grading of biopsy specimens according to guidelines from the International Society of Urological Pathology. 12 Biopsy and RP grades were also reported according to recently proposed prognostic Gleason grade groups, which range from 1 to 5. 13 Biopsy tissue was not regraded according to 2014 International Society of Urological Pathology criteria. All biopsy and RP specimens were centrally examined within each of the 3 participating centers. Follow-up after RP occurred according to each center's standard protocol: physical examination plus PSA at 6 to 12 weeks, then every 3 to 6 months for 1 to 5 years, and then annually. Computed tomography and/or bone scans were prompted by abnormal examinations and/or labs.
The pooled analysis included 1981 patients with NCCN high-risk PCa who underwent RP. Of these, 602 (30%) were classified as VHR (Table 1) . The proportion of patients who underwent presurgical ADT was 17% (29% among VHR men and 12% among non-VHR men; P < .001; Table 2 ).
Statistical Analysis
Separating patients with high-risk PCa into non-VHR and VHR risk strata, we tabulated and compared demographic, clinical, and pathologic characteristics; we used chi-square tests for comparing proportions, t tests for comparing means, and Wilcoxon rank-sum tests for comparing medians for nonnormally distributed variables.
VHR PCa was defined according to Johns Hopkins University criteria proposed in 2013: primary Gleason pattern 5 on biopsy, >4 biopsy cores with a Gleason sum of 8 to 10, or multiple individual NCCN high-risk features. 5 The time to BCR was defined on the basis of the first PSA level ≥ 0.2 ng/mL or the receipt of secondary RT and/or ADT (whichever was earlier). METS was defined as radiographically detectable bony, soft tissue, or visceral neoplastic disease, and cancer-specific mortality (CSM) was defined as death secondary to PCa progression. All-cause mortality (ACM) was defined as death from any cause.
The associations of VHR PCa with BCR, METS, and CSM were evaluated with univariate and multivariable competing risks regression models. Competing events in the absence of BCR were defined as METS or ACM events. Competing events in the absence of METS and CSM were defined as ACM events. ACM was evaluated in univariate and multivariable Cox proportional hazards models. Multivariable models were adjusted for age, race, center, year of treatment and receipt of presurgical ADT. Prognostic Kattan preoperative nomogram scores were also calculated for each patient. 14 The goodness of fit of VHR and nomogram scores for modeling oncologic outcomes was assessed with Harrell's concordance (c) index. This cooperative study was approved by all institutions' human investigation review boards, and all statistical analyses were performed with Stata 13.1. Cancer February 1, 2019
RESULTS
Adverse pathologic features were more frequent among men who met VHR criteria (Table 2) . Compared with patients with high-risk PCa who did not meet VHR criteria, VHR patients were more likely to sustain positive surgical margins (37% vs 25%; P < .001) and pathologic lymph node METS (pN1, 37% vs 15%; P < .001).
The median follow-up was 40.7 months (interquartile range [IQR], 20-66 months), and it was similar between the groups (Table 2) . Overall, there were 845 BCR events, 202 METS events, 34 CSM events, and 84 ACM events. Men who died of PCa were more likely to have met VHR criteria (76% vs 24%; P < .001).
The association of presurgical ADT with pathologic outcomes was analyzed. ADT was associated with lower rates of positive surgical margins. For the entire cohort, the rates of positive surgical margins were 30% in the absence of ADT and 20% with ADT (P < .001). Among VHR patients, the rate of positive surgical margins was 43% with presurgical ADT and 23% with ADT (P < .001). For the entire cohort, the pN1 rate was 20% for men who received presurgical ADT and 36% for men who received ADT (P < .001). Among VHR patients, the pN1 rate was 37% with presurgical ADT and 45% with ADT (P = .075). For the entire cohort, the rate of stage pT3b to T4 was 22% in the absence of presurgical ADT and 42% with ADT (P < .001). Among VHR patients, the pT3b to T4 rates were 40% with presurgical ADT and 56% with ADT (P < .001). Five-year cumulative event rates were higher among VHR men than high-risk patients (Table 3) . VHR criteria were strongly associated with the hazards for BCR, METS, PCa-specific mortality, and ACM, with adjustments made for clinical and demographic variables (Table 4 and Fig. 1 ). The receipt of presurgical ADT was not independently associated with BCR, CSM, or ACM. In the multivariable competing risks regression of METS after treatment, the subdistribution hazard ratio of presurgical ADT was 1.55 (95% confidence interval, 1.02-2.36; P = .042).
We then tested the associations of the commonly used Kattan prognostic nomogram with classification as VHR or non-VHR. Kattan nomogram scores represent the probability of freedom from BCR 5 and 10 years after treatment with RP. 14 was observed between the non-VHR and VHR groups. Cox proportional hazards models for BCR, METS, CSM, and ACM were fit with the prognostic variable of interest (VHR classification or Kattan nomogram score) with the treatment year, center of treatment, and race as covariates. Areas under the receiver operating characteristic curve suggested that the VHR classification was a more accurate model of METS and CSM (c indices, 0.690 and 0.811, respectively), whereas the preoperative Kattan nomogram modeled BCR more accurately (c index, 0.630; Table 5 ).
DISCUSSION
Here we have validated criteria for VHR PCa as a risk stratum that identifies men with worse pathologic features and oncologic outcomes after surgery for localized PCa. These criteria may be useful for counseling individual patients regarding the treatment and prognosis for high-risk disease and the risk of needing subsequent postoperative therapies. As a corollary, VHR criteria should also be considered as a risk-stratification tool in future clinical protocols. Before the VHR criteria were originally proposed in 2013, 5 multiple groups had demonstrated that subsets of men with high-risk PCa appeared to have worse oncologic outcomes after RP (Table 6 ). We propose the VHR criteria described herein as a simple, validated clinical prognostic tool because they have robust associations with METS, CSM, and ACM. Although the purpose of this study was not to compare pretreatment prognostic tools, we performed an exploratory analysis of Kattan nomogram (preoperative 5-year BCR) scores between high-risk and VHR groups because of the wide clinical use of the Kattan nomogram. It is not surprising that the Kattan score is a better fit for BCR (its intended use). The c indices of VHR with METS and CSM indicate a superior model fit, and this is expected because the Cancer February 1, 2019 VHR criteria were originally proposed for their strength of association with those specific outcomes. In agreement with this observation, we note that for men with highrisk (non-VHR) PCa and patients with VHR PCa, who have divergent oncologic outcomes, there is substantial overlapping in their range of Kattan nomogram scores. This underlies the importance and utility of the VHR classification as a prognostic tool for men with high-risk PCa. In exploratory analyses, we analyzed prognostic associations with the receipt of presurgical ADT. Although there was an association of presurgical ADT with METS after treatment, this study was not designed to assess the independent prognostic or therapeutic associations of the covariate presurgical ADT, and it should be interpreted accordingly.
Notably, recent NCCN guidelines propose a VHR classification 3 that is similar to the criteria that we originally derived 5 and are studying in the current analysis. The NCCN VHR stratum incorporates 1 element of a prior criterion for locally advanced PCa (clinical stage ≥ T3b) with 2 elements of the VHR criteria that have been validated in the current study (primary pattern 5 present on biopsy or >4 cores with a biopsy Gleason sum of [8] [9] [10] . The similarities between the NCCN VHR class and the formal VHR criteria are not coincidental because the guideline panel referenced the original VHR study in its work. As expected, the NCCN risk classification has been shown to be prognostic in a cohort of 4000 men with high-risk PCa who underwent RP. 20 It is possible that NCCN and other guideline panels may wholly adopt VHR criteria because of their current validation as PCa risk strata are refined for future clinical use.
The limitations of this study include its retrospective design and lack of central pathologic review (although all biopsy and pathologic slides were themselves centrally reviewed within each referral center). We did not exclude patients from the study on the basis of the total number of biopsy cores, and this could have affected high-risk stratification versus VHR stratification if a high-grade tumor nodule was either undersampled or oversampled. The time to BCR was defined on the basis of a PSA level ≥ 0.2 ng/mL or the receipt of secondary RT and/or ADT (whichever was earlier) to best capture the natural history of progression and clinically actionable endpoints in this high-risk PCa cohort. This was because the initiation of secondary therapies was at the discretion of the individual patient and treating physician, so secondary ADT and/or RT administered in the setting of a detectable PSA level < 0.2 ng/mL may have led to treatment-related prolongation of the time to BCR if it had been analyzed strictly by PSA. Our analyses of ACM did not incorporate individual patient comorbidities because these data were not uniformly available among institutions. Given the competing risk of non-PCa-specific deaths, we used competing risks regressions to analyze the other oncologic endpoints in this study: BCR, CSM, and METS. The use of presurgical ADT was greater among VHR patients; although we controlled for this confounder in our regression models, this is an imperfect adjustment that can be evaluated only in a prospective fashion. Similarly, the use of postsurgical RT and/or ADT was greater (as expected) among VHR patients. Despite this disparity, oncologic outcomes were worse in the VHR group, and this supports the notion that standard treatment approaches are not adequate for VHR PCa.
Among frontline management options for PCa, RT plus ADT is another important option for men who either are ineligible for RP or elect not to undergo RP. Notably, VHR criteria have also been studied in single-center cohorts of men undergoing primary RT plus ADT. Narang et al 11 analyzed a cohort of patients with high-risk PCa undergoing RT plus ADT at Johns Hopkins and found that those with VHR PCa also had worse oncologic outcomes at 10 years (distant METS, 32% vs 8%; P < .01; CSM, 13% vs 4%; P < .01). Tomita et al, 22 studied an adapted VHR definition (primary biopsy Gleason pattern 5, >4 biopsy cores with a Gleason sum of 8-10, or clinical stage T4) and found that among high-risk men, VHR criteria were associated with a higher risk of clinical recurrence over a median follow-up of 68 months (adjusted hazard ratio, 20; P = .004).
Taken together, these findings suggest that VHR PCa is a clinically relevant risk stratum that identifies men with worse pathologic and oncologic outcomes after standard localized treatment approaches in comparison with men with high-risk criteria alone. From now on, as suggested by Mano et al, 21 the collective challenge for physicians treating PCa is to develop improved treatment approaches (using multiple modalities along with novel systemic agents in clinical trial settings) that allow men with VHR PCa to achieve durable cancer control. VHR criteria will be a necessary stratification factor for consideration in neoadjuvant, presurgical, and adjuvant/salvage clinical trials to ensure adequate randomization.
In conclusion, VHR PCa criteria are a risk stratum that is independently validated and associated with a substantially higher rate of METS and CSM after RP. Because men with VHR PCa have inferior cancer control with standard curative and salvage therapies, we propose
